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Myeloid-derived suppressor cells (MDSCs) are a group of myeloid cells composed of hematopoietic progenitor
cells, immature macrophages, dendritic cells, and granulocytes, which accumulate in inﬂammatory diseases
and various cancers. Here, we investigated the dynamic changes and effects of MDSCs in graft-versus-host
disease (GVHD) development and/or tumor relapse after syngeneic and allogeneic bone marrow trans-
plantation (BMT). We found that adding functional MDSCs in donor graft alleviated GVHD, whereas removal
of MDSCs in vivo exacerbated GVHD. After T cell-deplete BMT, MDSCs transiently accumulated in the blood
and spleen of recipients without GVHD. In contrast, after T cell-replete BMT, the levels of blood MDSCs were
constantly elevated in recipients with GVHD. MDSC accumulation positively correlated with the severity of
GVHD. Additionally, MDSC accumulation was further increased upon tumor relapse. Although MDSCs isolated
from both syngeneic and allogeneic BMT recipients inhibited T cell proliferation in response to alloantigen
stimulation ex vivo, MDSCs from the recipients with GVHD showed much higher suppressive potency
compared with those from recipients without GVHD. These results indicate that MDSCs can regulate the
immune response in acute GVHD, and possibly tumor relapse, subsequent to allogeneic BMT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION “Natural suppressor cells” were found in the spleens of
Myeloid-derived suppressor cells (MDSCs) are a hetero-
geneous cell population that includes immature myeloid
cells and the progenitor cells of macrophages, dendritic cells
(DCs), monocytes, and neutrophils. Accumulation of MDSCs
was originally found in cancer patients [1-3]. Because MDSCs
inhibit T cell activation and help tumor cells evade attack
from the host immune system, they are regarded as “bad”
cells with no beneﬁcial effects to humans. Contrary to that
opinion, ﬁndings indicate that MDSCs may play an immune
regulatory role in infectious diseases, autoimmune diseases,
and inﬂammatory diseases. Acute Trypanosoma cruzi infec-
tion has been found to induce T cell activation, increase the
production of interferon-g (IFN-g), and subsequently lead to
MDSC expansion [4,5]. In a mouse model of multiple scle-
rosis, accumulation ofMDSCswas observed in the spleen and
blood, and these cells were found to enter the central
nervous system during the inﬂammatory phase of the
disease [6]. The apparent function of accumulated MDSCs in
infectious and inﬂammatory disease is to regulate the
immune response in a “reasonable” scope and prevent tissue
damage.edgments on page 701.
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13.01.008clinical bone marrow transplantation (BMT) recipients and
suppressed T cell proliferation under the stimulation of
alloantigen or mitogen [7-11]. Their myeloid origin, accu-
mulation, and suppressive function in individuals with
cancer was conﬁrmed 10 years later when excessive
numbers of CD34þ myeloid cells were noted in the blood of
patients with head and neck squamous cell carcinoma
[12,13]. Graft-versus-host disease (GVHD) is the result of
attack of allogeneic donor T cells on multiple host organs and
is a signiﬁcant cause of morbidity and mortality after allo-
geneic BMT. Host myeloid-derived cells, such as DCs acting as
antigen-presenting cells (APCs), are important mediators for
the initiation of GVHD [14,15]. Donor APCs transferred with
the graft or differentiated from hematopoietic progenitor
cells drivemore extensive tissue injury by cross-presentation
of host alloantigens [16]. As the precursors of DCs and
macrophages, the role ofMDSCs in the pathogenesis of GVHD
is not clear.
There are few studies on MDSCs in the setting of alloge-
neic BMT. It was reported that MDSCs accumulated in blood
peaked in number at week 3 and returned to the physio-
logical level at week 12 in minor histocompatibility-
mismatched BMT recipients, suggesting a regulatory role of
MDSCs in GVHD [17]. In vitro or in vivo cytokine
stimulationegenerated MDSCs alleviated GVHD in murine
allogeneic BMT models [18,19]. It is unclear, however, how
MDSC accumulation affects GVHD. In the current study, weTransplantation.
D. Wang et al. / Biol Blood Marrow Transplant 19 (2013) 692e702 693showed that differentiation of MDSCs with all-trans retinoic
acid (ATRA) signiﬁcantly aggravated GVHD, whereas
supplement of MDSCs to donor graft alleviated GVHD, indi-
cating MDSCs regulated GVHD development in vivo.
We further studied the kinetics of MDSC accumulation in
allogeneic BMT recipients and tested their immune
suppressive function in vitro. We found that MDSCs accu-
mulated in the blood and spleens of BMT recipient mice
(both allogeneic and syngeneic BMT) and gradually reduced
to physiological levels if GVHD did not occur. MDSC accu-
mulation in the blood was closely associated with the
development of GVHD. Tumor relapse further increased
MDSC accumulation in blood and spleen even in the recipi-
ents after allogeneic BMT. The accumulated MDSCs signiﬁ-
cantly inhibited allogeneic T cell proliferation.
METHODS
Mice
BALB/c (H-2d), FVB/NCr (H-2q, termed FVB), C57BL/6 (H-2b, termed B6),
and B6  DBA2 F1 (H-2b/d, termed B6D2F1) mice were purchased from the
National Institutes of Health (Bethesda, MD). Luciferase transgenic mice on
B6 background were kindly provided by Dr. Robert Negrin (Stanford
University, Stanford, CA). All the mice were housed in pathogen-free
conditions at H. Lee Mofﬁtt Cancer Center. All experimental procedures
were approved by the Institutional Animal Care and Use Committee.
Reagents and Chemicals
The following antibodies speciﬁc for mouse antigens were used for cell
surface staining for ﬂow cytometry or T cell puriﬁcation: anti-Gr-1 FITC
(clone RB6-8C5), anti-Gr-1 biotin (clone RB6-8C5), anti-CD4-FITC, anti-CD4-
APC (L3T4), anti-CD8a-FITC, anti-CD8a-APC, anti-H-2Kb-FITC, anti-
CD11b-PE-Cy7, anti-CD11b-biotin, anti-B220-biotin, anti-DX5-biotin, and
anti-Ter119-biotin were purchased from eBioscience (San Diego, CA). Anti-
Ly6G FITC (clone 1A8) and anti-Ly6C APC (clone AL-21) were purchased
from BD Bioscience (San Jose, CA). Anti-Thy1.2 (clone 30H12), anti-CD3
(clone 2C11), and anti-CD28 (clone 37.51) were purchased from BioXCell
(West Lebanon, NH). Young rabbit complement was purchased from GTI
Diagnostics (Waukesha, WI). ATRA was purchased from Sigma Aldrich (St.
Louis, MO). ATRA was dissolved in dimethyl sulfoxide (DMSO), stored in
e20 freezer, and diluted in phosphate-buffered saline (PBS) before use.
Carboxyﬂuorescein diacetate, succinimidyl ester (CFSE) was purchased from
Invitrogen (Grand Island, NY). Catalase and uric acid were purchased from
Sigma Aldrich L-NG-Monomethylarginine, Acetate Salt (L-NMMA). and n-
omega- Hydroxy-nor-L-arginine (Nor-NOHA) were purchased from Cayman
Chemical (Ann Arbor, MI).
Cell Preparation
T cells were puriﬁed through negative selection using magnetic bead
depletion of noneT cells. Brieﬂy, after lysis of red blood cells, spleen and
lymph node cells were incubated with biotin-conjugated anti-CD11b, anti-
B220, anti-DX5, and anti-Ter119 for 15 minutes in .1% bovine serum albumin
(BSA)-PBS at 4C. Cells were subsequently washed and incubated with anti-
biotin beads (Miltenyi, Auburn, CA) for 15minutes at 4C in .1% BSA-PBS, and
antibody-bound cells were removed magnetically using LS column (Milte-
nyi). T cell purity was normally over 95%. Mouse bone marrow cells were
harvested by ﬂushing femurs and tibias with 1% fetal calf serum RPMI-1640.
T cells were removed by incubation with anti-Thy-1 antibody (4C, 30 min)
followed by incubation with young rabbit complement (37C, 45 min).
MDSCswere isolated from recipient spleens and bonemarrow by incubation
with anti-Gr-1 biotin antibody (4C, 15 min) followed by washing and
incubation with anti-biotin beads (4C, 15 min). Cells other than MDSCs
were removed magnetically by LS column sorting. MDSC purity was typi-
cally between 90% and 95%.
Bone Marrow Transplantation
BALB/c mice were exposed to total body irradiation (TBI) at 800 cGy (a
single dose) using a Shepherd Mark I Cesium Irradiator (J.L. Shepherd and
Associates, San Fernando, CA) at day e1. If B6 or B6D2F1 mice were used as
recipients, the dose of TBI was 1,200 to 1,300 cGy (two split doses). Irradiated
recipients received a single intravenous injection in the lateral tail vein of
T celledepleted bone marrow cells (TCD-BM) with or without T cells within
24hours. The severityofGVHDwasassessedbymice survival and loss of body
weight. In addition, systemic GVHD was scored based on 5 clinical parame-
ters: weight loss, posture (hunching), activity, fur texture, and skin integrity.
Individual mice were scored 0 to 2 for each criteria and 0 to 10 overall [20].Leukemia or Lymphoma Models
To mimic clinical tumor relapse, we used lymphoma or leukemia cell
lines in the B6 / BALB/c and B6 /B6D2F1 BMT models, respectively. In
BALB/c recipients, the A20 B lymphoma cell line transduced with a luc/neo
plasmid (A20-luc) was used to allow for visualization of tumor dissemina-
tion. Mice received 800 cGy TBI on day e1. On day 0, BALB/c recipients
received grafts containing 5  106 TCD-BM with or without .1  106 T cells
and various numbers of A20-luciferase-expressing cells (A20-Luc) as indi-
cated in corresponding ﬁgures. In the B6/B6D2F1 BMT model, mice
received 1,200 to 1,300 cGy TBI on day e1. On day 0, B6D2F1 recipients
received grafts containing 5  106 TCD-BM with 2 to 4  106 T cells and
1  104 host type P815 (DBA/2-derived, H-2d) tumor cells.
To further mimic clinical tumor relapse, we also used an inducible
model of chronic myeloid leukemia (CML). MSCV2.2 expressing the human
p210 bcr/abl cDNA and enhanced green ﬂuorescent protein (EGFP) driven by
an internal ribosome entry site (Mp210/GFP) was a gift from Dr. Warren
Shlomchik (Yale, New Haven, CT). Retroviral supernatants were generated
by way of transient transfection of the Platinum-E Retroviral Pack cell line
(Cell Biolabs, San Diego, CA) as described previously [16,21]. In short, on day
e1, 4  106 Platinum-E Retroviral Pack cells were seeded on 6-cm plates in
Dulbecco-modiﬁed Eagle medium with 10% fetal calf serum. On day 0, the
cells were transfected with 8 mg Mp210/GFP using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Thirty-six hours after transfection, the media was
changed. Retroviral supernatants were harvested 12 hours later, ﬁltered
through .45-mm screens, and stored in aliquots at e80C.
To establish CML in mice, BALB/c were injected with 5 mg of
5-ﬂuorouracil (Sigma-Aldrich) on day e6. On day e2, BM cells were har-
vested and cultured in prestimulation medium (Dulbecco-modiﬁed Eagle
medium, 15% fetal bovine serum (FBS), 6 ng/mL interleukin [IL]-3, 10 ng/mL
IL-6, and 10 ng/mL Stem cell factor (SCF) all cytokines were from Peprotech,
Rocky Hill, NJ). On day e1 and 0, cells were resuspended at 2 106/mL in
prestimulation medium with the addition of the retroviral supernatants
Polybrene (4 mg/mL; Sigma-Aldrich) and HEPES (100 mM) and underwent
spin infection (1,000g, 37C, for 1.5 hours). BM cells were returned to a CO2
incubator for 2 hours after each spin infection. On day 0, 2 105 infected BM
cells along with 5  106 TCD-BALB/c BM cells were transferred to lethally
irradiated BALB/cmice. BALB/c recipientswere bledweekly fromweek 1, and
CD11bþGFPþ leukemia cells were monitored by ﬂow cytometry. Premorbid
CMLmicewerekilled, and2106CMLBMandsplenocytes alongwith5106
TCD-B6 BM cells were transferred to lethally irradiated BALB/c mice to
establish spontaneous CML in recipient mice.
In Vivo Bioluminescence Imaging
Mice were given an intraperitoneal injection of luciferin (150 mg/kg
body weight) and then anesthetized with isoﬂurane gas using an XGI Gas
anesthesia system (Xenogen, Cranbury, NJ) and imaged using the IVIS
imaging system (Xenogen, Cranbury, NJ) to assess bioluminescence (BLI)
10 minutes after injection of the substrate. Imaging data were analyzed and
quantiﬁed with Living Image Software (Xenogen) as described in our
previous work [22].
Mixed Lymphocyte Reaction
B6 T cells and BALB/c splenic APCs were isolated from spleen and lymph
node using magnetic column selection with biotin antibodies and anti-
biotin magnetic beads. TCD-splenic cells from BALB/c mice were irradiated
at 2,000 cGy. CFSE-labeled 2105 puriﬁed B6 Tcells were used as responder
and 6  105 BALB/c TCD-splenic cells as stimulators. Cells were cultured in
96 round-bottom plates for 5 days, and the proliferation of B6 T cells was
measured by ﬂow cytometry.
T Cell Proliferation
A 48-well plate was coated with 10 mg/mL anti-CD3 antibody and 5 mg/
mL anti-CD28 antibody in PBS at 4C, overnight. The coated plate was
washed with 1% fetal bovine serum RMPI-1640 two times before use. CFSE-
labeled 2  105 puriﬁed B6 T cells were seeded in the plate with different
concentrations of ATRA. T cell proliferation was measured by CFSE dilution
in 72 hours.
Statistical Analysis
The log-rank test was used to detect statistical differences in recipients’
survival in GVHD experiments. Student’s t-test was used in other
experiments.
RESULTS
MDSCs Accumulate in Allogeneic BMT Recipients
To relate MDSCs to GVHD development, we monitored
the presence of MDSCs over time in the blood and spleens of
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syngeneic BMT recipients, MDSCs accumulated in blood and
spleens at week 2 but declined gradually to the levels of the
control mice without BMT. No signiﬁcant difference was
detected between recipients that underwent transplantation
with TCD-BM alone and TCD-BM plus T cells at any time
point tested (Figure 1A,C). In the B6 / BALB/c allogeneic
BMT model, MDSC accumulation was also transient in
recipients of TCD-BM alone; however, MDSC accumulation
was prolonged in recipients of TCD-BM plus T cells
(Figure 1B,C). Because severe hypocellularity was caused by
acute GVHD in the recipients of TCD-BM plus T cells, the
absolute numbers of MDSCs in recipient spleen at week 4
were comparable between two groups (data not shown).
Anti-Gr-1 antibody binds to the common epitope of Ly6G
and Ly6C. Accordingly, MDSCs can be further divided into
granulocytic MDSCs (CD11bþLy6GþLy6Clow) and monocytic
MDSCs (CD11bþLy6GLy6Chi), as shown in Figure 1D.
Previous studies showed these two MDSC populations
had different functions in cancer and infectious disease
[6,23,24]. We studied the accumulation of both MDSC pop-
ulations in syngeneic and allogeneic BMT. Similar to theBlood  MDSC
Ly6G
+
Ly6C
low
   Ly6G
-
Ly6C
high
       Ly6G
+
Ly6C
low
Ly6G
-
Ly6C
high
%
 
M
D
S
C
 
i
n
 
d
o
n
o
r
 
c
e
l
l
s
0
20
40
60
80
Allo BM alone
Allo BM+T cell
Syn BM alone
Syn BM+T celln.s
n.s
n.s
n.s
Week 2                                            Week 4
n.s
**
n.s
*
0           2               4              6               8
%
 
M
D
S
C
 
i
n
 
d
o
n
o
r
 
c
e
l
l
s
0
10
20
30
40
Week
n.s
n.s n.s
n.s
BM  alone
BM  + T  cells
Syngeneic   BMT
Control
2
4
6
8
%
 
M
D
S
C
 
i
n
 
d
o
n
o
r
 
c
e
l
l
s
MDSC in Spleen
%
 
 
M
D
S
C
 
i
n
 
d
o
n
o
r
 
c
e
l
l
s
0
20
40
60
80
              0                Week 2                   Week 4
n.s
n.s
n.s
***
Allo BM alone
Allo BM+T cell
Syn BM alone
Syn BM+T cell
B6 Control
BALB/c Control
Figure 1. MDSCs accumulated in recipients after BMT. BALB/c or B6 mice (n ¼ 4) were
without 1  106 T cells from B6 donors. The percentage of donor-derived MDSCs, H-2
every other week after BMT. (A) Kinetics of blood MDSCs in syngeneic BMT recipients f
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independent experiments, and one representative experiment was shown. n.s. indicaCD11bþGr-1þ population, granulocytic and monocytic MDSC
subpopulations accumulated at week 2 and quickly declined
in the blood and spleens of recipients without GVHD
(Figure 1E,F). In contrast, accumulation of both subpopula-
tions maintained at high levels for a long period of time in
the recipients with GVHD. To exclude the possibility that this
phenomenonwas BMTmodel speciﬁc, we performed similar
experiments using another major histocompatibility
complex (MHC)-mismatched BMT model (FVB/N/ BALB/c)
and also found that the sustained MDSC accumulation was
only observed in BM-plus-splenocyte recipients with GVHD
(Supplementary Figure S1).
Accumulated MDSCs Are Immune Suppressive
To test the function of CD11bþGr-1þ cells accumulated in
BMT recipients, we performed a series of mixed lymphocyte
reaction (MLR) using CFSE-labeled T cells from B6 mice as
responders and TCD-splenocytes from BALB/c mice as
stimulators. As shown in Figure 2A, MDSCs isolated from
allogeneic recipients at week 2 signiﬁcantly inhibited T cell
proliferation. Similarly, MDSCs from syngeneic recipients 2
weeks after BMT were also immune suppressive (Figure 2B). Spleen  MDSC
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GVHD 4 weeks after BMT showed signiﬁcantly higher
suppressive activity than those fromrecipientswithoutGVHD
(Figure 2C). Because arginase 1, inducible nitric oxide syn-
thase, reactive oxygen species, and peroxynitrite are potential
mediators for immune suppression by MDSCs [25-28], we
tested which molecules mediated MDSCs’ immune suppres-
sion by using speciﬁc inhibitors to block each of these path-
ways. As shown in Figure 2D, catalase (H2O2 scavenger,
antagonize reactive oxygen species) and Nor-NOHA (arginase
inhibitor) efﬁciently reversed the immune suppressive func-
tion of MDSCs, whereas L-NMMA (inducible nitric oxide
synthase inhibitor) and uric acid (peroxynitrite scavenger)
did not have an effect. Therefore, the suppressive function of
MDSCs in the setting of BMT was arginase-1 and reactive
oxygen species dependent. In addition, we explored the
possibility that the suppressive function of MDSCs was MHC
dependent. We observed similar suppression of the prolifer-
ation of MHC-matched and unmatched T cells, suggesting
MDSCs can mediate immune suppression in an MHC-
independent manner (data not shown).Accumulation of MDSCs in BMT Recipients Correlated
with the Severity of GVHD
To test the hypothesis that the accumulation of MDSCs
correlated with the severity of GVHD, we transplanted
various numbers of T cells from B6 donors into allogeneic
BALB/c recipients to induce GVHDwith various severities and
compared the kinetics of MDSC accumulation across groups
of recipients. According to weight loss (Figure 3A), the
severity of GVHD positively correlated with the number of
donor T cells transplanted. MDSC accumulation occurred in
the peripheral blood of all recipients 2 weeks after BMT
(Figure 3B). Recipients that underwent transplantation with
.5106 donor Tcells showed the highest percentage ofMDSC
accumulation among all groups at weeks 4 and 6. Recipients
of .1  106 T cells displayed moderate MDSC accumulation,
whereas recipients of .02  106 T cells showed no difference
in MDSC accumulation compared with BM alone. Further-
more, donor T cells induced MDSC accumulation in the
recipients’ spleens in a dose-dependent manner at week 6
(Figure 3C). Thus, the accumulation of MDSCs positively
correlated to the severity of GVHD after allogeneic BMT.
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We next explored whether accumulated MDSCs were
immune suppressive and regulated GVHD in vivo. ATRA
induces apoptosis of granulocytic MDSCs and differentiates
monocytic MDSCs to mature myeloid cells including
macrophage and DCs [29-32]. ATRA treatment signiﬁcantly
reduced the absolute number of MDSCs in the spleens of
recipients that underwent transplantation with TCD-BM
alone (Figure 4A). Splenic reconstitution, survival, and
weight loss were not affected by ATRA treatment (Figure 4B-
D). To test the potential impact of MDSCs in the development
of GVHD, we used ATRA to reduce MDSC numbers after
allogeneic BMT. ATRA treatment signiﬁcantly reduced the
total number of MDSCs in recipient spleens (Figure 4E).
Recipients treated with ATRA died from GVHD signiﬁcantly
sooner than vehicle-treated controls (Figure 4F). To exclude
the possibility that ATRA accelerated GVHD by enhancing T
cell activation, we tested the effect of ATRA on T cell response
to anti-CD3/CD28 stimulation in vitro and found that T cell
proliferation was not affected by treatment with ATRA in
a wide range of concentrations (Supplementary Figure S2).
Hence, our current data suggest that ATRA-induced reduc-
tion of MDSCs likely contributed to the accelerated GVHD.Adoptive Transfer of In Vivo-Generated MDSCs Alleviated
GVHD
Because removal of MDSCs was associated with acceler-
ated GVHD, we further tested the hypothesis that trans-
ferring MDSCs at the time of BMT would alleviate GVHD.
Granulocyte colony-stimulating factor (G-CSF) was used to
induce accumulation of functional MDSCs in mice, as previ-
ously shown [33]. MDSCs were deﬁned as CD11bþGr-1þ cells,
including the Gr-1 high and Gr-1 medium cell populations
(Figure 5A). Percentages of MDSCs were much higher
in G-CSFetreated B6 mice, as shown in Figure 5B. G-
CSFeprimed MDSCs inhibited T cell proliferation underallogeneic stimulation in vitro (data not shown). Cotransfer-
ring splenicMDSCs fromG-CSFetreated B6mice signiﬁcantly
alleviated GVHD in BALB/c recipients that underwent trans-
plantation with TCD-BM plus T cells from normal B6 donors
(P< .05). MDSCs isolated from the BM of G-CSFetreatedmice
delayed GVHD, but Gr-1þCD11bþ cells isolated from the BM
of vehicle-treated mice accelerated GVHD as reﬂected by
survival, body weight loss, and clinical scores (Figure 5D-F).
Consistent with clinical manifestations, total cells and donor-
derived B cells in recipient spleens were also signiﬁcantly
preserved by additional MDSCs (Figure 5G,H). Additional
MDSCs had no effect on donor engraftment, as full-donor
chimerismwas achieved in all the recipients (Supplementary
Figure S3). We did not test MDSCs from the spleens of PBS-
treated mice due to low numbers of MDSCs in these mice.
To measure the effect MDSCs on donor T cell expansion,
we repeated the BMT experiment by using T cells from
luciferase transgenic mice on the B6 background. Consistent
with recipient lethality and weight loss, transferred splenic
MDSCs from G-CSFetreated B6 mice also signiﬁcantly
reduced T cell expansion, as reﬂected by strength of the BLI
signal. Conversely, BM-derived MDSCs from vehicle-treated
mice enhanced T cell expansion (Figure 5C). In addition,
vehicle-treated BMGr-1þCD11bþ cells signiﬁcantly increased
IFN-g production by donor CD4þ and CD8þ T cells, whereas
G-CSF-treated splenic MDSCs signiﬁcantly decreased IFN-g
production by CD8þ T cells in the liver (Figure 5I) and in the
spleen (Figure 5J). Hence, cotransfer of functional MDSCs at
the time of allogeneic BMT signiﬁcantly reduced T cell acti-
vation and expansion and thus alleviated GVHD.Tumor Relapse Further Increased MDSCs Accumulation
Originally, MDSC accumulation was found in cancer
patients, and tumor relapse is a major threat for BMT
patients. To study the affects of tumor relapse on MDSC
accumulation after BMT, we quantiﬁed MDSC accumulation
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Figure 4. Removal of MDSC using ATRA aggravated GVHD. BALB/c mice were lethally irradiated and underwent transplantation with 5  106 TCD-BM alone (A-D) or
with 1 106 T cells (E and F) from B6 donors. Recipient mice were treated with ATRA (RA, 1.25 mg/kg body weight) or solvent control via i.p. injection every other day
from day 0 to day 12. Some mice were euthanized on day 14 to analyze the accumulation of MDSCs in the spleen. (A) ATRA treatment reduced MDSC number in the
spleen of the recipients with TCD-BM alone. (B) ATRA treatment did not affect spleen reconstitution without GVHD. ATRA treatment had no effect on survival (C) or
body weight (D) in the recipients of with TCD-BM alone. In the recipients that underwent transplantation with TCD-BM plus T cells, ATRA treatment reduced MDSC
number in the spleen (E), aggravated GVHD, and accelerated lethality (F) (n ¼ 13-14). (A-E) show representative data from three replicate experiments that produced
similar results. (F) shows pooled results from 3 replicate experiments. n.s. indicates no signiﬁcant difference, * P < .05, ** P < .01, *** P < .001.
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ated BALB/c mice underwent transplantation with TCD-BM
and T cells from B6 donors with or without different
numbers of A20-Luc lymphoma cells. Recipients that under-
went transplantation with TCD-BM alone and 1  104 A20-
Luc cells quickly relapsed, but an additional .1  106 donor
Tcells essentially prevented lymphoma relapse (Figure 6A, B).
Even at a high dose of lymphoma (5  104 A20-Luc cells),
additional donor T cells were able to reduce the rate of tumor
growth (Figure 6A, B). By examining the presence ofMDSCs in
recipient blood and spleens, we found that tumor relapse
caused signiﬁcantly higher levels of MDSC accumulation in
the recipients of TCD-BM alone without GVHD and in the
recipients of TCD-BM plus T cells with GVHD (Figure 6C, D).
There was no difference in MDSC accumulation among the
recipients of TCD-BM plus T cells with or without tumor
infusion, however, as long as relapse was prevented. To
exclude the possibility that this phenomenon was BMT
model or tumor type speciﬁc, we performed similar
experiments using another MHC-mismatched BMT model
(B6/ B6D2F1) with p815-luciferase-expressing (P815-Luc)
mastocytoma cells. Under these experimental conditions,
only mild and self-limited GVHD was observed, and tumorrelapse further increased MDSC accumulation in recipients
with or without GVHD (Supplementary Figure S4). Thus, we
conclude that tumor relapse enhanced MDSC accumulation
after BMT regardless of GVHD.
Because transplantable tumors may not represent well
clinical leukemia/lymphoma relapse, we further established
a “spontaneous” CML mouse model by transfecting BM with
P210 bcr/abl, which was then transferred into lethally irra-
diated syngeneic hosts as described in the Methods section.
CML underwent transplantation with TCD-BM alone or plus
T cells from B6 donors. CML growth was monitored by
measuring GFPþCD11bþ cells and MDSCs as Gr-1þCD11bþ
cells in recipient blood and spleens. Within 3 weeks, CML
relapse was evident in BALB/c recipients that underwent
transplantation with BM and splenocytes from CML mice, as
GFPþCD11bþ cells were present in the blood and spleens of
these recipients but not control recipients (Figure 7A).
Accordingly, the percentages of MDSCs in blood and spleens
were signiﬁcantly higher in CML mice compared with
controls without CML (Figure 7A). In the presence of donor T
cells, the growth of CML was dramatically reduced
(Figure 7B,C). Consequently, the increased MDSC accumula-
tion by CML was reverted.
Figure 5. Cotransferring functional MDSCs alleviated GVHD after allogeneic BMT. B6 mice were subcutaneously injected 10 mg per mouse with human G-CSF or PBS
daily from day 0 to day 4. Four hours after the last injection, MDSCs were isolated from the spleen and BM. MDSCs were cotransferred at 2 106 per mouse to lethally
irradiated BALB/c mice that received TCD-BM and 1 106 T cells from B6 donors. Body weight was monitored twice a week, and survival was recorded daily. In some
experiments, donor T cells were isolated from luciferase transgenic B6 mice to monitor the in vivo proliferation. (A) Splenocytes were stained for the expression of
H-2Kb, CD11b, and Gr-1, and MDSCs were deﬁned as H2Kbþ/CD11bþ/Gr-1þ. (B) MDSCs accumulated in G-CSFetreated mice spleen, bone marrow, and blood. (C) Donor
T cell proliferation in vivo reﬂected by average BLI signal at days 5, 10, and 14 after BMT. Recipient survival (D), body weight changes (E), and GVHD clinical score (F)
are shown. Donor engraftment is shown by total spleen cell number (G) and B cell number (H) at day 28. (I and J) show the percentages of IFN-gesecreting T cells in
recipient spleen or liver at day 14. The data represent one of 3 replicate experiments. *P compared with BMþT cell group. n.s. indicates no signiﬁcant difference,
* P < .05, ** P < .01, *** P < .001.
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GVHD or Tumor Relapse
Both GVHD and tumor relapse after BMT enhanced MDSC
accumulation. We further asked whether the composition of
MDSCs was different under these 2 situations. B6/ BALB/cBMT plus A20 tumor model was used, and phenotypes of
MDSCs were measured 3 weeks after BMT (Figure 8A). We
found that both granulocytic (CD11bþLy6GþLy6Clow) and
monocytic (CD11bþLy6GLy6Chi) MDSCs were signiﬁcantly
increased in GVHD or tumor relapse, although more
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Figure 6. A20 tumor relapse further increased MDSC accumulation. BALB/c mice (n ¼ 4) were lethally irradiated and underwent transplantation with TCD-BM plus
.1  106 B6 T cells with various numbers of A20-Luc cells. The A20-Luc growth in vivo was monitored by BLI. The percentages of MDSCs in blood and spleen were
determined with ﬂow cytometry. (A) A20-Luc growth in vivo, reﬂected by BLI signal strength. (B) Average intensity of BLI signal for each experimental group. (C) The
percentage of blood MDSCs at day 14. (D) The percentage of spleen MDSCs at day 18. Similar results were obtained from 2 independent experiments and 1
representative experiment was shown. n.s. indicates no signiﬁcant difference, * P < .05, ** P < .01, *** P < .001.
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granulocytic versus monocytic MDSC were comparable
among 3 groups, indicating the composition of MDSCs was
not different (Figure 8C). We also compared the immune
suppressive potential of MDSCs in the recipients with GVHD
or tumor relapse mice. At lower T cell-to-MDSC ratio, the
MDSCs from the recipients with tumor relapse were more
potent than those with GVHD (Supplementary Figure S5).
DISCUSSION
Previous work by others suggests that MDSCs accumulate
in murine models of allogeneic BMT [17,34], but the rela-
tionships between MDSC accumulation, GVHD severity, and
tumor relapse was not clear. Here, we systemically studied
the accumulation of MDSCs in allogeneic and syngeneic BMT
recipients. We found that MDSCs accumulated in both
syngeneic and allogeneic BMT mice in the ﬁrst 2 weeks,
which indicates the initial MDSC accumulation was not
related to GVHD but rather resulted from TBI-induced stress
at an early stage of BMT. The proinﬂammatory cytokine
release initiated by TBI, including IFN-g, G-CSF, IL-1b, andIL-6, makes an ideal microenvironment for the accumulation
and activation of MDSCs [35-37]. In the absence of GVHD,
those elevated proinﬂammatory cytokines gradually
returned to basal levels in parallel with the recovery of host
tissue. Accordingly, MDSC percentage in mice declined to
basal levels at week 4. Once GVHD developed, the escalated
proinﬂammatory cytokines continued stimulating the
expansion and accumulation of MDSCs (as seen in recipients
transplanted with allogeneic BM plus T cells). GVHD also
increased MDSC percentage by interfering with bone
marrow and spleen reconstitution at later time points. These
results indicate that GVHD development supports the
constant accumulation of MDSCs over time. In fact, we
observed a positive correlation between the levels of MDSCs
in peripheral blood and the severity of GVHD.
In clinical hematopoietic cell transplantation, tumor
relapse is a major threat to patients. We studied whether
tumor relapse further increases MDSC accumulation in
allogeneic BMT recipients. Our results showed that tumor
relapse stimulated the additional accumulation of MDSCs
in the peripheral blood and spleens of recipients after
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Figure 7. Spontaneous tumor (CML) relapse increased MDSC accumulation. BALB/c mice (n ¼ 4) were lethally irradiated and transplanted with B6 TCD-BM alone as
control or plus 2 106 CML-BM and CML-splenocytes to mimic CML relapse in the recipient mice. MDSC and CML cells in blood and spleen were analyzed at week 3.
(A) CML cell and MDSC in the blood and spleen of control mice and CML mice. (B) The percentage of MDSC in donor cells and the percentage of CML cells among total
white blood cells. (C) The percentage of MDSC in donor cells and the percentage of CML cells in total spleen cells. One representative experiment from 3 independent
experiments was shown. n.s. indicates no signiﬁcant difference, * P < .05, ** P < .01, *** P < .001.
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predict tumor relapse.
In this study, Gr-1 and CD11b were used to identify
MDSCs, although other cell types may also express these 2
markers, such as neutrophils and granulocytes. Hence,
phenotype alone was not enough to identify MDSCs, and the
gold standard was the immune suppressive functional study.
We found that MDSCs isolated from both allogeneic and
syngeneic BMT recipients were indeed immune suppressive.
The immune suppressive efﬁciencies were quite similar at
week 2 but differed signiﬁcantly at week 4 indicating the
occurrence of GVHD not only kept MDSC accumulation
constant but also maintained MDSC immune suppressive
efﬁciency at high levels. Previous studies have attributed
MDSCs’ suppressive functions to arginase-1, inducible nitric
oxide synthase, reactive oxygen species, and/or peroxynitrite
[25-27,38]. Here we demonstrated that the suppressive
functions of MDSCs in allogeneic BMT were arginase-1 and
reactive oxygen species dependent. We did not see a reversal
effect of L-NMMA on MDSCs. The possible reason is that we
tested the combination of both granulocytic and monocytic
MDSCs, whereas L-NMMA was only effective on monocytic
MDSCs [23]. Considering the larger proportion (>75%) of
granulocytic MDSCs in the mixture, it is possible that the
effect through L-NMMA was not visible.
MDSCs accumulate in many pathological conditions and
facilitate the evasion of tumor immunity in patients;
however, studies have indicated that MDSCs may play
a regulatory role in disease progression. In allogeneic BMT,exogenous MDSCs alleviate GVHD in mice [18,19]. Therefore,
manipulatingMDSCsmay be a promising strategy to regulate
GVHD after allogeneic BMT. Here we showed that removal of
MDSC with ATRA signiﬁcantly accelerated GVHD. We ratio-
nalize that ATRA treatment removed MDSCs by either
depleting or differentiating MDSCs. Because acute GVHD is
initiated by host APCs, and donor APCs contribute to the
maximal GVHD [16], it is possible that increased conversion
of donor APCs by ATRA treatment might also attribute to
accelerated GVHD. Our data showed ATRA did not affect T cell
proliferation under the stimulation of anti-CD3 and anti-
CD28 Abs in vitro, which indicated T cells might not be the
key target for ATRA treatment, although we cannot exclude
this possibility.
Given that accumulated MDSCs in BMT recipients were
sufﬁcient to suppress allogeneic T cell proliferation in vitro, it
is not clear why they were incapable of preventing GVHD
in vivo. One possibility is that the accumulation of MDSCs
occurred later than the activation and proliferation of allo-
geneic T cells in vivo, and thus those MDSCs had no chance to
control ongoing GVHD. In support of this hypothesis, Paraiso
et al. showed that SH2 domain–containing inositol 5-
phosphatase (SHIP) deﬁciency resulted in a rapid and
signiﬁcant expansion of MDSCs in peripheral lymphoid
tissues of recipient mice before receiving a T cell-replete BM
graft, which led to the abrogation of acute GVHD [39]. This
work and the work of others showed that MDSCs isolated
in vivo from G-CSFetreated mice or MDSCs generated
in vitro with various cytokines signiﬁcantly prevented GVHD
FSC-A
SS
C-
A
23.1
<PerCP-Cy5-5-A>: H-2kb
SS
C-
A
98.7
<PE-Cy7-A>: CD11b
SS
C-
A
59.3
FSC-A
SS
C-
A
57
<PerCP-Cy5-5-A>: H-2kb
SS
C-
A
81.4
<PE-Cy7-A>: CD11b
SS
C-
A
22.1
FSC-A
SS
C-
A
60.5
<PerCP-Cy5-5-A>: H-2kb
SS
C-
A
85.9
<PE-Cy7-A>: CD11b
SS
C-
A
21.3
BM+T cell
BM alone
BM+A20
0102 103 104 105
Ly6G
0
102
103
104
105
Ly
6C
15.4
40.6
0102 103 104 105
Ly6G
0
102
103
104
105
Ly
6C
13
44.6
0102 103 104 105
Ly6G
0
102
103
104
105
Ly
6C
16.3
35.9
%
 i
n
 d
o
n
o
r
 c
e
ll
B
M
 a
lo
n
e
B
M
+
T
 c
e
ll
B
M
+
A
2
0
B
M
 a
lo
n
e
B
M
+
T
 c
e
ll
B
M
+
A
2
0
0
5
10
15
20
25
Ly6G
+
Ly6C
low
Ly6G
-
Ly6C
high
***
 **
 **
***
 *
 **
L
y
6
G
+
/
L
y
6
C
h
i
g
h
B
M
 a
lo
n
e
B
M
+
T
 c
e
ll
B
M
+
A
2
0
0
1
2
3
4
n.s
Figure 8. The composition ofMDSC is similar in the spleen of GVHDor tumor-relapsedmice. BALB/cmice (n¼ 5)were lethally irradiated and underwent transplantation
with B6 TCD-BM alone or plus 1  106 B6 T cells or 1 103 A20-Luc cells. Mice were euthanized on day 21, and the percentages of MDSC subpopulations in recipient
spleens were analyzed. (A) Phenotype of donor-derived granulocytic (CD11bþLy6GþLy6Clow) and monocytic (CD11bþLy6GLLy6Chigh)) MDSCs. (B) Percentage of donor-
derived granulocytic andmonocytic MDSCs. (C) The ratio of granulocytic versusmonocytic MDSC. n.s. indicates no signiﬁcant difference, * P< .05, ** P< .01, *** P< .001.
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lymphocyte infusion causes less severe GVHD [40], which
would support the idea that early accumulation of MDSCs
before T cell infusion is required to suppress T cell activation
and thus reduce GVHD development.
Importantly, Gr-1þCD11bþ cells isolated from PBS-treated
mice BM accelerated GVHD, because the Gr-1þCD11bþ cells
were physiologically immature myeloid cells, which further
differentiated into DCs andmacrophages posttransplantation
and promoted GVHD development [30,41]. It is noteworthy
that MDSC isolated from the spleen and bone marrow of G-
CSFetreated mice showed a signiﬁcantly different GVHD
preventive effect (Figure 5D-F). The possible explanation is
that there were more than 30% Gr-1þCD11bþ cells in bone
marrow but less than 5% in spleen of normal mice. Because
these cells are immature myeloid cells without suppressive
function, a substantially higher proportion of these immature
myeloid cells in bone marrow would dilute the functional
MDSCs newly generated in mice treated with G-CSF, which
resulted in a reduced efﬁcacy of total MDSCs isolated from
BM in the prevention of GVHD.
In summary, we showed that the accumulation of MDSCs
was positively correlated with GVHD severity. Although
these MDSCs had a regulatory activity to suppress T cell
responses to alloantigens, they were not sufﬁcient to control
GVHD development under routine allogeneic BMT condi-
tions. However, we provide evidence that adding functional
MDSCs at the time of BMT signiﬁcantly alleviated GVHD,whereas removal of MDSCs correlated with accelerated
GVHD, indicting MDSCs have a direct relevance to GVHD
development. It cannot be denied that MDSCs are a double-
edged sword for allogeneic BMT patients, as they negatively
regulate GVHD development but also facilitate tumor
growth. Maintaining a delicate balance of MDSCs may
present a challenging but promising approach for the control
of GVHD and tumor relapse after allogeneic BMT.ACKNOWLEDGMENTS
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